Short Reads

Product liability under Directive 85/374: a potential defect, is a defect too

Product liability under Directive 85/374: a potential defect, is a defect too

Product liability under Directive 85/374: a potential defect, is a defect too

02.12.2015 NL law

In its decision of 5 March 2015 (joined cases C-503/13 and C-504/13), in reply to preliminary questions of the German Bundesgerichtshof, the European Court of Justice (ECJ) clarified that under Directive 85/374 an implantable medical device can be considered defective for the mere reason that the product belongs to a group or series of products that has a potential risk of being defective. If the product belongs to that group or series of products, there is no need to establish that the individual product actually suffers from that defect as well.

In 2005, Boston Scientific, a producer of medical devices, found that a particular type of pacemaker it produced had a substantially higher chance of being defective than normal according to its own standards. As a result, Boston Scientific recommended that physicians replace the pacemakers, which would be provided free of charge. Around the same time, Boston Scientific also found that a particular type of implantable cardioverter defibrillator might be affected by a defect as well. Therefore, Boston Scientific recommended that physicians mitigate the consequences of such potential defect by deactivating a certain switch of the implantable cardioverter defibrillator.

Although the pacemakers were free of charge and the implantable cardioverter defibrillator did not need to be replaced, the patients (or their health insurers) still incurred  the costs of the surgery and hospital stay. For this reason, two of the health insurers (AOK Sachsen-Anhalt-Gesundheidskasse and Betriebskrankenkasse RWE) involved decided to seek recourse against Boston Scientific for damages for death and personal injury under article 9(1) of the Directive, as transposed into German product liability law.

During the legal proceedings before the German courts, Boston Scientific disputed that the pacemakers and implantable cardioverter defibrillators involved were defective.

Under article 4 of the Directive, the burden of proving the defect, the damage and the causal relationship between defect and damage lies with the injured person and, following subrogation, with their health insurers. As the pacemakers were destroyed after their removal without any expert examination, the health insurers would have severe difficulties in proving any defect. After all, these pacemakers and the implantable cardioverter defibrillator were not removed because they had a defect, they were removed because the possibility  of these devices having a defect was higher than normal according to Boston Scientific’s standards.

After the health insurers won the case before the German courts in two instances, the German Bundesgerichtshof decided to ask the ECJ preliminary questions about – in short – the interpretation of the notions of “defect” and “death and personal injury” under the Directive, in the context of this case.

The ECJ ruled that to establish whether a product is defective, according to article 6(1) of the Directive, all circumstances must be taken into account including the presentation of the product, how it could reasonably be expected to be used and when it was put into circulation. The safety one may expect from a product is to be established by considering the purpose of the product. Given the purpose and in light of the particularly vulnerable situation of the patients using pacemakers and implantable cardioverter defibrillators, the ECJ stated that the safety requirements for these devices, which such patients are entitled to, are particularly high.

The potential lack of safety which would give rise to liability of the producer under the Directive, for this type of product, stems from the abnormal potential for damage which those products might cause to the person concerned. If the products involved belong to the same group or form part of the same production series that have a potential defect, it is possible to classify all the products of that group or series as defective without there being any need to prove that the individual product is defective as well. If and in so far as surgery and hospital stay is necessary to overcome the defect in that device in the product in question, the ECJ considers these costs damage caused by death or personal injury to be borne by the producer.

As a consequence of this decision, producers must be aware that, depending on the nature of their product, under certain circumstances they may need to compensate consumers for damages following a product recall, even where the individual products may not be defective.

In the Netherlands, it is less likely that health insurers will be able to successfully claim damages on the basis of Directive 85/374 in a similar case. Article 1 of the Directive is transposed into Dutch law by means of article 6:185 Dutch Civil Code (DCC) (liability for defective products). Under Dutch law (article 6:197 DCC), a Dutch insurer that has paid out the insurance proceeds to the person insured having recourse against the producer of defective products under article 6:185 DCC is explicitly excluded.

However, Dutch health insurers may be entitled to claim damages under article 6:162 DCC (liability for an unlawful act). In the event of a claim based on article 6:162 DCC, the health insurer has to prove that the producer of the device has committed an attributable unlawful act which has resulted in damages. This makes the threshold for a successful claim for damages on the basis of article 6:162 DCC, possibly higher than for a claim under 6:185 DCC.

The post Product liability under Directive 85/374: a potential defect, is a defect too is a post of stibbeblog.nl

Team

Related news

04.06.2019 NL law
Dutch Supreme Court clarifies evidentiary rules concerning signatures and signed documents

Short Reads - In two recent decisions, the Dutch Supreme Court has clarified the evidentiary power of signed documents. If the signatory unambiguously denies that the signature on the document is his or hers or claims that another party has tampered with the signature (for instance, through forgery or copying a signature from one document and pasting it in another), it is up to the party invoking the signed document to prove the signature's authenticity (ECLI:NL:HR:2019:572).

Read more

24.05.2019 NL law
European regulatory initiatives for online platforms and search engines

Short Reads - As part of the digital economy, the rise of online platforms and search engines raises all kinds of legal questions. For example, do bicycle couriers qualify as employees who are entitled to ordinary labour law protections? Or should they be considered self-employed (see our Stibbe website on this issue)? The rise of online platforms also triggers more general legal questions on the relationship between online platforms and their users. Importantly, the European Union is becoming increasingly active in this field.

Read more

03.06.2019 NL law
Toerekening van kennis van groepsvennootschappen

Articles - In de praktijk doet zich vaak de vraag voor of kennis die aanwezig is binnen de ene vennootschap kan worden toegerekend aan een andere vennootschap binnen hetzelfde concern. In dit artikel verkent Branda Katan zowel de dogmatische grondslag als de praktische toepassing van een dergelijke toerekening. Zij concludeert dat het ‘Babbel-criterium’ (heeft in de gegeven omstandigheden de kennis X in het maatschappelijk verkeer te gelden als kennis van Y?) geschikt is voor het toerekenen van kennis in concernverband.

Read more

01.05.2019 NL law
Arbitral award obligating Ecuador to prevent enforcement of USD 8.6 billion order does not violate public order

Short Reads - Due to environmental damage as a result of oil extraction in the Ecuadorian Amazon, oil company Chevron was ordered to pay USD 8.6 billion to Ecuadorian citizens. In order to claim release of liability, Chevron and Texaco initiated arbitration proceedings against Ecuador. Arbitral awards ordered Ecuador to prevent enforcement of the Ecuadorian judgment, leaving the Ecuadorian plaintiffs temporarily unable to enforce their judgment. According to the Supreme Court (12 April 2019, ECLI:NL:HR:2019:565), these arbitral awards did however not violate public order.

Read more

28.05.2019 NL law
Dutch court: insufficient substantiation? No follow-on cartel damages action

Short Reads - Dutch courts are forcing claimants (including claims vehicles) to be well-prepared before initiating follow-on actions. The Amsterdam District Court in the Dutch trucks cartel follow-on proceedings recently ruled that claimants – specifically CDC, STCC, Chapelton, K&D c.s. and STEF c.s. – had insufficiently substantiated their claims. These claimants now have until 18 September 2019 to provide sufficient facts regarding transactions that – according to them – were affected by the cartel. Preparation should thus be key for cartel damages actions.

Read more

01.05.2019 NL law
Termination of an agreement: compelling grounds?

Short Reads - When does a reason given for termination of an agreement qualify as a compelling ground? That was the central question in the Dutch Supreme Court's decision of 29 March 2019 (ECLI:NL:HR:2019:446). Depending on the nature of the agreement and the circumstances of the case, termination may only take place under certain conditions, e.g. only on compelling grounds. 

Read more

Our website uses functional cookies for the functioning of the website and analytic cookies that enable us to generate aggregated visitor data. We also use other cookies, such as third party tracking cookies - please indicate whether you agree to the use of these other cookies:

Privacy – en cookieverklaring